Automated and Rapid Microbiological Tests

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• Automated and Rapid Microbiological Tests: A Definition
• Clinical Applications
• Automated Identification and Susceptibility Systems
• Automated Blood Culture Systems
• Automated Tuberculosis Systems
• Streptococcal Infection Rapid Tests
• GC/Chlamydia Rapid Tests
• Other Automated & Rapid Microbiological Tests
• Non-Clinical Applications

II. EXECUTIVE SUMMARY

1. Industry Overview

• Outlook
• Evolutionary Battle Against the Bugs Drives the Future of the Market ...
• Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics Market
• Traditional Rapid Microbiological Tests Destined to Go Out With the Old
• A Current & Future Analysis
• Segmental Perspective
• Clinical Applications
• Non-Clinical Applications
• Macro: The Big Picture
• Deciding the Market' s Future...
• A Holistic Peek into a Few Noteworthy Trends
• Biotechnology & Rapid Microbial Tests
• Automated & Rapid Microbiological Tests: "Current Market Stance"
• A Business Case for Automated & Rapid Microbiological Testing
• Near Patient Testing: An Offshoot of Rapid Microbiological Tests
• Pros & Cons of Near Patient Testing
• Role of Near Patient Testing in Reducing Antibiotic Resistance in Humans
• The Pre/Post Microbial Rapid Testing Era: A Review
• Market Structure
• Competitive Setup of the Diverse Automated & Rapid Microbiology Products Market
• Historic Data
• Table 1: Leading Players in World Market for IVD Automated Microbiology Systems (2000) - Percentage Breakdown of Value Sales by Company forbioMerieux, Dade Behring, Becton Dickinson,Organon Teknika, and Others (includescorresponding Graph/Chart)

2. Trends & Issues

• Advancements in Molecular Diagnostics - A Boon or a Threat
• Antibiotic Resistant Bacteria Throws the Spotlight On Microbial Testing
• Instant Detection of Pathogens - A New Epoch in the Fight for Survival
• Lower Cost Rapid Tests Built on Multiple Sampling Modalities - Gaining Momentum
• "Time Constraints?" - Rapid Tests to the Rescue
• Rapid HIV Tests: A New Age Diagnostic Weapon Against the Killer Disease
• Accuracy/Reliability of Home HIV Testing: A Bone of Contention
• Development of Near Patient Test Kits: A Market Driven Phenomenon
• Near Patient Test Kits: A Rumination of Possibilities
• Automated Blood Culture Systems: A Winning Edge in the Fight Against Bacteremia
• Leading Food Processors Resort to Rapid Microbiological Testing
• Impact of Food Scares on Rapid Microbiological Tests Market
• Demand for Microbiological Tests & Level of QC in the Food Industry
• Rapid Tests Creating Brighter Avenues in Food Microbiology Testing Market
• Dire Need to Nip Operating Costs Throws the Spotlight on Rapid Tests
• Key Advantages/Benefits of Rapid Microbiological Tests on Food
• Food Packages of the Future Ingrained with Microbial Alert Systems
• Technology Innovations in Rapid Food Microbial Testing
• Obtaining Regulatory Approval - A Major Non-Technical Hindrance

3. Factors Influencing the Market

• Continuing Biological Warfare with Pathogens Sparks Market Growth ...
• Innovative Products - A Key Growth Strategy
• Other Market Drivers in a Capsule
• Low Turnaround Times Skyrocket Demand
• Greater Patient Awareness
• Rising Incidence of STDs Kindles Universal Market Acceptance
• Ultra-Rapid HIV-Screening Tests- A Strong Fight against HIV-Epidemic
• Validation of Rapid Microbiological Tests: An Imperative Prerequisite
• Non-Conformance to Testing Requirements: A Weighty Concern
• Influenza - Boosting Rapid Test Prospects

4. Product/Technology Overview

• Automated & Rapid Microbiological Tests: A Definition
• Benefits of Automated & Rapid Microbiological Tests
• Classification of Rapid Microbiological Test Methods
• How Does a Rapid Test Work?
• Sample Preparation - A Key Procedure
• Automated Identification and Susceptibility Systems
• Automated Blood Culture Systems
• Automated Tuberculosis Systems
• Microminiaturization of Diagnostic Tests: How Is It Effected?
• Advantages of Microminiaturisation:
• Acid-Fast Microscopy - The Forerunner of Rapid Tests
• Gram' s Stain: A Time-Honored & Rapid Method to Detect Pathogens in Blood
• Enabling Technologies of Automated & Rapid Microbiological Tests
• Growth-based Technologies
• Viability-based Technologies
• Cellular-Component or Artifact-based Technologies
• Genomics/ Proteomics
• Microarrays/ Microfluidics
• DNA Microchips/Probes
• Polymerase Chain Reaction (PCR)
• Immunoassay
• Immunoassay Escalates into Diverse Fields of Diagnostic Testing
• Nucleic Acid Testing (NAT)
• Nucleic Acid Probes
• Signal-Amplified Tests
• Nucleic Acid Amplification Tests
• Traditional Methods with Computer-Aided Imaging
• Combination Methods

5. End-Use Application Analysis

• Applications in Clinical Investigations
• STD Rapid Tests
• GC/Chlamydia Rapid Tests
• HIV Rapid Tests
• HIV Facts & Figures
• Advantages of Rapid HIV Testing
• Disadvantages of Rapid HIV Testing
• Syphilis Rapid Tests
• Respiratory Rapid Tests
• RSV/ Influenza Rapid Tests
• Tuberculosis Rapid Tests
• Group A beta Hemolytic Streptococcus Rapid Tests
• Mononucleosis Rapid Tests
• Streptococcus Rapid Tests
• Streptococcus A Rapid Tests
• Streptococcus B Rapid Tests
• Gastrointestinal Rapid Tests
• Giardia Lamblia Rapid Tests
• H. Pylori Rapid Tests
• Cryptosporidium Rapid Tests
• C. Difficile Rapid Tests
• Applications in Non-Clinical Investigations
• Food/Water Safety Tests
• Food Safety Testing: A Lucrative Application Area
• Rapid Microbiological Methods in Pharmaceutical Sector
• Limitations of RMMs
• Advantages of RMMs
• Applications in Pharmaceutical Sector
• Environmental Tests
• Other Miscellaneous Applications

6. Product Innovations/Introductions

• Meridian Bioscience Rolls Out Two New Rapid Tests for Detecting Epstein-Barr Virus
• Oxoid Introduces Staph Plus System for Identifying Staphylococcal Species
• Siemens Healthcare Diagnostics Launches MicroScan® WalkAway® plus Diagnostic Microbiology Systems
• Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelect™ test, in US
• bioMerieux Introduces VIDAS®, an automated Clostridium difficile A & B Toxins Detection Test
• Oxoid Launches Remel Wellcolex® Colour Tests for Testing Shigella, E. coli O157 and Salmonella
• Siemens Healthcare Diagnostics Obtains Health Canada Approval for its VERSANT 440 Molecular System
• Oxoid Unveils Remel Xpect™ Clostridium Difficile Toxin A/B Test
• Neogen Introduces Soleris System
• ATCC Introduces Authenticult™ Quality Control Microbiological Testing Tool
• Bio-Rad Introduces New EBV Kits
• Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test
• Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test
• FDA Clears Usage of TIGRIS® System for Testing WNV in Donated Blood
• FDA Approves ImmunoCard STAT!® EHEC for Detecting E. coli Infection
• bioMerieux Introduces TEMPO® Quality Indicator Testing System
• Biotrace Introduces Tecra Unique Campylobacter Rapid Test
• bioMerieux Introduces TEMPO® EB test for Enterobacteriaceae
• Roche Unveils Elecsys TORCH Assays
• Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan
• bioMerieux Develops Advanced Colorimetry™ NH Card
• Roche Introduces Rapid LightCycler SeptiFast Sepsis Test across EU
• Oxoid Launches New Rapid Test for Salmonella Detection in Food Products
• Oxoid Unveils New Contact Plate Design
• FDA Approves Fluconazole Susceptibility Tests from BioMerieux
• Polysciences Unveils New Microbiological & Bacterial Detection Applications
• Researchers Develop New Rapid MODS Test for TB Detection
• Dade Behring Unveils Automated Quadriga BeFree System
• FDA Approves Abbott PRISM® HBsAg Assay
• Bayer' s EHIV Test Receives FDA Clearance
• Gen-Probe Obtains FDA Approval to Use Aptima Test on Additional Specimens
• Roche Diagnostics' cobas TaqScreen MPX Test Receives CE Mark Approval
• Cepheid Introduces Rapid Xpert® MRSA Test in Europe
• Bio-Rad Widens Culture Media with Addition of RAPID' Salmonella
• Chemogen Develops New Tuberculosis Rapid Test
• bioMerieux Rolls Out VIDAS® LDUO Test
• Zonda Develops New Rapid Test for Chlamydia
• MedMira Launches MiraCare Rapid HIV Test
• STMicroelectronics and Mobidiag Unveil Lab-On-Chip
• Vermicon Launches ScanVIT-Legionella Rapid Test Kit
• New Line of Rapid Microbial Detection Systems from Centrus
• OraSure Rolls Out OraQuick ADVANCE
• Abbott Unveils Automated HCV Test
• ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and Respiratory Pathogens
• Biophage Pharma Offers Service for Microbiological Testing
• bioMerieux Releases New Rapid Test for Nosocomial Infections
• bioMerieux Widens Product Portfolio with Addition of TEMPO® System
• Celsis Introduces CellScan Innovate Rapid Screening System
• Millipore Rolls Out Rapid Microbiology Detection System
• Calypte Biomedical Develops Oral Fluid Rapid Test for HIV- 1/2
• BioMerieux Unveils VITEK® 2 Compact
• Bio-Rad Unveils New Test Kits and Comprehensive Automated Systems

7. Recent Industry Activity

• Becton, Dickinson Establishes New Rapid Diagnostic Products Manufacturing Facility in China
• Quidel Corporation Obtains CLIA Waiver from US FDA for its QuickVue® RSV Test
• Siemens Obtains US FDA Approval for its VERSANT™ 440 Molecular System
• bioMerieux to Market Wescor' s Customized Slide Stainer Instruments under bioMerieux Brand
• Schering-Plough and OraSure Ink Collaboration Agreement for Developing Rapid Oral HCV Test
• Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV-II Blood Screening Test
• Quidel and bioMerieux Form a Long-term Alliance in Rapid Diagnostic Tests
• BD Diagnostics Obtains US FDA Approval BD GeneOhm™ StaphSR assay
• Meridian Bioscience Obtains US FDA Approval for Two New Rapid Tests
• Siemens AG Acquires Dade Behring
• Thermo Fisher Scientific Teams Up with KBA for Expanding its Microbiology Business Division in Lenexa
• OraSure and SCMS Enter into an Agreement for Supplying OraQuick® HIV Test to PEPFAR Countries
• Abbott Obtains US FDA Approval for its Fully Automated PRISM® HCV Test
• Gen-Probe Obtains US FDA Approval for its PROCLEIX® TIGRIS® System for Testing Donated Blood
• AdvanDx Ropes In bioMerieux for Distributing its Rapid Diagnostic Tests in US
• 3M and Gen-Probe Join Hands to Develop Rapid Molecular Tests For Detecting HAIs
• Gen-Probe' s PROCLEIX® TIGRIS® System Obtains US FDA Approval for Screening Donated Blood for West Nile Virus
• 3M Acquires Acolyte Biomedica
• Formation of Siemens Medical Solutions Diagnostics
• bioMerieux Bags Contract to Provide VITEK® 2 System for Scottish NHS Labs
• bioMerieux Licenses NorChip' s HPV Test Technology for Cervical Cancer
• bioMerieux in Strategic Agreement with Cepheid for Sepsis Assays
• 3M Health Care Creates New Medical Diagnostics Unit
• Schering-Plough & OraSure to Develop Rapid Oral HCV Test
• 3M Acquires Biotrace International
• Siemens Acquires DPC
• Oxoid Acquires Microbiology Business Activities of Dako
• Inverness Acquires IDT and Thermo BioStar
• BMD in Agreement with MND for Research on Diagnostic Tests
• Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus Detection Test
• Dutch Government Grants ?7.9 Million to FIND
• FIND and Hain to Develop Rapid Test for MDR and XDR TB
• 3M & Gen-Probe Ally for Developing Rapid Molecular Tests for Food Safety
• Continuing Biological Warfare with Pathogens Sparks Market Growth ...
• Innovative Products - A Key Growth Strategy
• Other Market Drivers in a Capsule
• Low Turnaround Times Skyrocket Demand
• Greater Patient Awareness
• Rising Incidence of STDs Kindles Universal Market Acceptance
• Ultra-Rapid HIV-Screening Tests- A Strong Fight against HIV-Epidemic
• Validation of Rapid Microbiological Tests: An Imperative Prerequisite
• Non-Conformance to Testing Requirements: A Weighty Concern
• Influenza - Boosting Rapid Test Prospects

4. Product/Technology Overview

• Automated & Rapid Microbiological Tests: A Definition
• Benefits of Automated & Rapid Microbiological Tests
• Classification of Rapid Microbiological Test Methods
• How Does a Rapid Test Work?
• Sample Preparation - A Key Procedure
• Automated Identification and Susceptibility Systems
• Automated Blood Culture Systems
• Automated Tuberculosis Systems
• Microminiaturization of Diagnostic Tests: How Is It Effected?
• Advantages of Microminiaturisation:
• Acid-Fast Microscopy - The Forerunner of Rapid Tests
• Gram' s Stain: A Time-Honored & Rapid Method to Detect Pathogens in Blood
• Enabling Technologies of Automated & Rapid Microbiological Tests
• Growth-based Technologies
• Viability-based Technologies
• Cellular-Component or Artifact-based Technologies
• Genomics/ Proteomics
• Microarrays/ Microfluidics
• DNA Microchips/Probes
• Polymerase Chain Reaction (PCR)
• Immunoassay
• Immunoassay Escalates into Diverse Fields of Diagnostic Testing
• Nucleic Acid Testing (NAT)
• Nucleic Acid Probes
• Signal-Amplified Tests
• Nucleic Acid Amplification Tests
• Traditional Methods with Computer-Aided Imaging
• Combination Methods

5. End-Use Application Analysis

• Applications in Clinical Investigations
• STD Rapid Tests
• GC/Chlamydia Rapid Tests
• HIV Rapid Tests
• HIV Facts & Figures
• Advantages of Rapid HIV Testing
• Disadvantages of Rapid HIV Testing
• Syphilis Rapid Tests
• Respiratory Rapid Tests
• RSV/ Influenza Rapid Tests
• Tuberculosis Rapid Tests
• Group A beta Hemolytic Streptococcus Rapid Tests
• Mononucleosis Rapid Tests
• Streptococcus Rapid Tests
• Streptococcus A Rapid Tests
• Streptococcus B Rapid Tests
• Gastrointestinal Rapid Tests
• Giardia Lamblia Rapid Tests
• H. Pylori Rapid Tests
• Cryptosporidium Rapid Tests
• C. Difficile Rapid Tests
• Applications in Non-Clinical Investigations
• Food/Water Safety Tests
• Food Safety Testing: A Lucrative Application Area
• Rapid Microbiological Methods in Pharmaceutical Sector
• Limitations of RMMs
• Advantages of RMMs
• Applications in Pharmaceutical Sector
• Environmental Tests
• Other Miscellaneous Applications

6. Product Innovations/Introductions

• Meridian Bioscience Rolls Out Two New Rapid Tests for Detecting Epstein-Barr Virus
• Oxoid Introduces Staph Plus System for Identifying Staphylococcal Species
• Siemens Healthcare Diagnostics Launches MicroScan® WalkAway® plus Diagnostic Microbiology Systems
• Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelect™ test, in US
• bioMerieux Introduces VIDAS®, an automated Clostridium difficile A & B Toxins Detection Test
• Oxoid Launches Remel Wellcolex® Colour Tests for Testing Shigella, E. coli O157 and Salmonella
• Siemens Healthcare Diagnostics Obtains Health Canada Approval for its VERSANT 440 Molecular System
• Oxoid Unveils Remel Xpect™ Clostridium Difficile Toxin A/B Test
• Neogen Introduces Soleris System
• ATCC Introduces Authenticult™ Quality Control Microbiological Testing Tool
• Bio-Rad Introduces New EBV Kits
• Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test
• Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test
• FDA Clears Usage of TIGRIS® System for Testing WNV in Donated Blood
• FDA Approves ImmunoCard STAT!® EHEC for Detecting E. coli Infection
• bioMerieux Introduces TEMPO® Quality Indicator Testing System
• Biotrace Introduces Tecra Unique Campylobacter Rapid Test
• bioMerieux Introduces TEMPO® EB test for Enterobacteriaceae
• Roche Unveils Elecsys TORCH Assays
• Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan
• bioMerieux Develops Advanced Colorimetry™ NH Card
• Roche Introduces Rapid LightCycler SeptiFast Sepsis Test across EU
• Oxoid Launches New Rapid Test for Salmonella Detection in Food Products
• Oxoid Unveils New Contact Plate Design
• FDA Approves Fluconazole Susceptibility Tests from BioMerieux
• Polysciences Unveils New Microbiological & Bacterial Detection Applications
• Researchers Develop New Rapid MODS Test for TB Detection
• Dade Behring Unveils Automated Quadriga BeFree System
• FDA Approves Abbott PRISM® HBsAg Assay
• Bayer' s EHIV Test Receives FDA Clearance
• Gen-Probe Obtains FDA Approval to Use Aptima Test on Additional Specimens
• Roche Diagnostics' cobas TaqScreen MPX Test Receives CE Mark Approval
• Cepheid Introduces Rapid Xpert® MRSA Test in Europe
• Bio-Rad Widens Culture Media with Addition of RAPID' Salmonella
• Chemogen Develops New Tuberculosis Rapid Test
• bioMerieux Rolls Out VIDAS® LDUO Test
• Zonda Develops New Rapid Test for Chlamydia
• MedMira Launches MiraCare Rapid HIV Test
• STMicroelectronics and Mobidiag Unveil Lab-On-Chip
• Vermicon Launches ScanVIT-Legionella Rapid Test Kit
• New Line of Rapid Microbial Detection Systems from Centrus
• OraSure Rolls Out OraQuick ADVANCE
• Abbott Unveils Automated HCV Test
• ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and Respiratory Pathogens
• Biophage Pharma Offers Service for Microbiological Testing
• bioMerieux Releases New Rapid Test for Nosocomial Infections
• bioMerieux Widens Product Portfolio with Addition of TEMPO® System
• Celsis Introduces CellScan Innovate Rapid Screening System
• Millipore Rolls Out Rapid Microbiology Detection System
• Calypte Biomedical Develops Oral Fluid Rapid Test for HIV- 1/2
• BioMerieux Unveils VITEK® 2 Compact
• Bio-Rad Unveils New Test Kits and Comprehensive Automated Systems

7. Recent Industry Activity

• Becton, Dickinson Establishes New Rapid Diagnostic Products Manufacturing Facility in China
• Quidel Corporation Obtains CLIA Waiver from US FDA for its QuickVue® RSV Test
• Siemens Obtains US FDA Approval for its VERSANT™ 440 Molecular System
• bioMerieux to Market Wescor' s Customized Slide Stainer Instruments under bioMerieux Brand
• Schering-Plough and OraSure Ink Collaboration Agreement for Developing Rapid Oral HCV Test
• Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV-II Blood Screening Test
• Quidel and bioMerieux Form a Long-term Alliance in Rapid Diagnostic Tests
• BD Diagnostics Obtains US FDA Approval BD GeneOhm™ StaphSR assay
• Meridian Bioscience Obtains US FDA Approval for Two New Rapid Tests
• Siemens AG Acquires Dade Behring
• Thermo Fisher Scientific Teams Up with KBA for Expanding its Microbiology Business Division in Lenexa
• OraSure and SCMS Enter into an Agreement for Supplying OraQuick® HIV Test to PEPFAR Countries
• Abbott Obtains US FDA Approval for its Fully Automated PRISM® HCV Test
• Gen-Probe Obtains US FDA Approval for its PROCLEIX® TIGRIS® System for Testing Donated Blood
• AdvanDx Ropes In bioMerieux for Distributing its Rapid Diagnostic Tests in US
• 3M and Gen-Probe Join Hands to Develop Rapid Molecular Tests For Detecting HAIs
• Gen-Probe' s PROCLEIX® TIGRIS® System Obtains US FDA Approval for Screening Donated Blood for West Nile Virus
• 3M Acquires Acolyte Biomedica
• Formation of Siemens Medical Solutions Diagnostics
• bioMerieux Bags Contract to Provide VITEK® 2 System for Scottish NHS Labs
• bioMerieux Licenses NorChip' s HPV Test Technology for Cervical Cancer
• bioMerieux in Strategic Agreement with Cepheid for Sepsis Assays
• 3M Health Care Creates New Medical Diagnostics Unit
• Schering-Plough & OraSure to Develop Rapid Oral HCV Test
• 3M Acquires Biotrace International
• Siemens Acquires DPC
• Oxoid Acquires Microbiology Business Activities of Dako
• Inverness Acquires IDT and Thermo BioStar
• BMD in Agreement with MND for Research on Diagnostic Tests
• Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus Detection Test
• Dutch Government Grants ?7.9 Million to FIND
• FIND and Hain to Develop Rapid Test for MDR and XDR TB
• 3M & Gen-Probe Ally for Developing Rapid Molecular Tests for Food Safety
• Bio View Inks Three-Year Distribution Agreement with Abbott Molecular
• Bodycote Acquires Foodscan Laboratories
• Cepheid Bags STTR Funding for Development of Rapid TB Test
• Abbott and Verax in Distribution Agreement for Verax Platelet PGD® Test
• BSL Supplies ABBOTT PRISM® System to Blood Donor Testing Centers
• Abbott & ARC in Agreement for Automated Blood Screening Tests
• BD to Set Up Production Facility for Rapid Diagnostic Products in China
• BD Diagnostics Delivers STI Testing Products to BioReference
• Meridian Licenses LAMP Diagnostic Test Technology from Eiken
• OraSure Inks Multi-Year Purchase Contract with New York City
• Abbott Inks Single-Source Agreement with Novation for HIV Test
• Neogen Takes Over Centrus International
• Becton, Dickinson and Company Acquires GeneOhm Sciences
• Inverness Medical Innovations Makes a Synergetic Purchase of ACON Laboratories
• Quest Diagnostics Strikes Deal with BD Diagnostics
• Novation Inks Pact with Abbott for Rapid HIV-1/2 Antibody Test
• TREK Diagnostic and Novation Inks Agreement
• Clinton Foundation Inks Agreement with Four Companies to Cut Prices
• Chembio Obtains FDA Approval for HIV 1/2 Stat-Pak and Sure Check HIV 1/2 Rapid Test PMAs
• Roche' s LightCycler SeptiFast Test Attains CE Mark
• Zonda Expands Distribution of Products in Europe
• OraSure Wins Rapid HIV Tests Order
• MedMira Secures Orders for Rapid HIV Tests
• Cepheid Collaborates with Foundation for Innovative Diagnostics
• Chembio Obtains Clearance for Rapid HIV Tests in Kenya
• Genesis Bioventures Bags US Patent for Rapid Prion- Detection Assay
• MedMira Obtains CE Mark for MiraCare
• Setema to Distribute Chembio' s Rapid HIV Tests in Ethiopia
• Clinton Foundation HIV/AIDS Initiative Selects Chembio to Provide Rapid HIV Tests
• Quidel Acquires immunochemical Fecal Occult Blood Test
• Xact Aid Snaps Up STD Alert
• Grant Life Sciences Acquires Rapid Tests from AccuDx
• Millipore Ties Up with Gen-Probe
• Foundation for Innovative New Diagnostics forms Collaboration with Eiken Chemical
• WayPoint and Global Rapid Diagnostic Leader Enter into an Agreement
• Akers Biosciences Enters into a Distribution Agreement with Alco Industries
• Celsis and BioVentures Enter into Licensing Agreement
• Thermo Electron Inks Pact with Genomic Profiling Systems
• Abbott and OraSure Enters into Agreement for OraQuick ADVANCE Rapid HIV-1/2 Test
• bioMerieux Signs Agreement with Novel Diagnostics
• Dade Behring Bags FDA Approval for Antimicrobial Susceptibility Test Panels
• OraSure Bags HCV Patent License from Chiron and Ortho- Clinical Diagnostics
• BD Diagnostics Receives FDA Approval for BD Directigen™ EZ Flu A+B Test
• BD Diagnostics Bags FDA Clearance for BBL™ CHROMagar™ MRSA Product
• MedMira Obtains Rights to Market Rapid HIV Tests in Guizhou Province, China
• Gen-Probe Obtains FDA Clearance for PROCLEIX® West Nile Virus Assay
• Medical Services International Secures Clearance for Rapid Test Kits
• Medical Services International Receives Exclusive Marketing Rights for TB Test Kit
• Adaltis Receives Orders for HIV Rapid Tests from China
• MedCap Bags Exclusive Distribution Rights for Syphilis Rapid Test
• Genomic Profiling Systems Obtains NIAID Funds to Develop Testing Platform
• Gen-Probe Obtains US Patent for Automated Process for Nucleic Acid Testing
• Bio-Rad Receives Approval for HIV-1/HIV-2 Rapid Test
• Cambrex Makes a Synergetic Purchase of Genolife
• Cambrex Bioproducts Acquires Worldwide License from Epoch Biosciences
• Cambrex Forges Licensing Agreement with John Hopkins University
• Calypte Biomedical and Adaltis Enters into an Agreement
• Calypte Biomedical Signs MoU with Pacific Biotech
• GlaxoSmithKline Process Employing Pall Rapid Test Receives FDA Approval
• Binax Receives FDA Approval for NOW Influenza A & B Rapid Test
• Spectral Diagnostics and IDx Inc. Announce US$12 Million R&D Project
• Genome Therapeutics Transfers Streptococcus Pneumoniae Patent to Aventis
• Abbott Inks an Agreement with BioGenex Laboratories
• Bio-Rad and Enzon Announce Marketing Agreement
• bioMerieux and Omnimed Join Forces to Fight Against AIDS

8. Focus on Select Global Players

• Abbott Laboratories (USA)
• Abbott Diagnostics (USA)
• Becton Dickinson and Company (USA)
• bioMerieux (France)
• bioMerieux, Inc. (USA)
• Bio-Rad Laboratories (USA)
• Cellabs Pty Ltd (Australia)
• Celsis International Plc (UK)
• Coris BioConcept (Belgium)
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Gen-Probe Incorporated (USA)
  • Genzyme Diagnostics (USA)
  • Inverness Medical Innovations, Inc. (USA)
  • Unipath Limited (UK)
  • MedMira Inc. (Canada)
  • Meridian Biosciences, Inc. (USA)
  • Orasure Technologies, Inc. (USA)
  • Orion Diagnostica Oy (Finland)
  • Quidel Corporation (USA)
  • Siemens Medical Solutions Diagnostics (USA)
  • Thermo Fisher Scientific, Inc. (USA)
  • Remel, Inc. (USA)
  • Oxoid Limited (UK)

9. Global Market Perspective

• Table 2: World Recent Past, Current & Future Market Analysis for Automated and Rapid Microbiological Tests by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 3: World Long-term Projections for Automated and Rapid Microbiological Tests by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 4: World 10-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 5: World Recent Past, Current & Future Market Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includescorresponding Graph/Chart)
• Table 6: World Long-term Projections for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 7: World Recent Past, Current & Future Market Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems,Streptococcal Infection Rapid Tests, GC/Chlamydia RapidTests and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 8: World Long-term Projections for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia RapidTests and Other Automated & Rapid Microbiological Tests IndependentlyAnalyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 9: World 10-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applicationsby Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World forYears 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 10: World 10-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used - Percentage Breakdown of Revenues for Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia RapidTests and Other Automated & Rapid Microbiological Tests for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 11: World Recent Past, Current & Future Market Analysis for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 12: World Long-term Projections for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia RapidTests and Other Automated & Rapid Microbiological Tests IndependentlyAnalyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 13: World 10-Year Perspective for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 14: World Recent Past, Current & Future Market Analysis for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 15: World Long-term Projections for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 16: World 10-Year Perspective for Automated Blood Culture Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 17: World Recent Past, Current & Future Market Analysis for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 18: World Long-term Projections for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 19: World 10-Year Perspective for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 20: World Recent Past, Current & Future Market Analysis for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 21: World Long-term Projections for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 22: World 10-Year Perspective for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 23: World Recent Past, Current & Future Market Analysis for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 24: World Long-term Projections for GC/Chlamydia RapidTests (*) in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 25: World 10-Year Perspective for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 26: World Recent Past, Current & Future Market Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010(includes corresponding Graph/Chart)
• Table 27: World Long-term Projections for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 28: World 10-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 29: World Recent Past, Current & Future Market Analysis for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US,Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 30: World Long-term Projections for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 31: World 10-Year Perspective for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • A Current & Future Analysis...
  • Rapid Microbiology Tests - A Competitive Profile
  • Consolidation in the Automated and Rapid Microbiological Tests Market
  • Bioterrorism Tests - Gaining Prominence
  • Tracking Trends Across Product Segments
  • STD Rapid Tests
  • Market Share Trends of Leading Players:
  • Table 32: Leading Players in the US Market for GC/Chlamydia Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Gen-Probe, Abbott, Becton Dickinson and Roche (includes corresponding Graph/Chart)
  • Table 33: Leading Players in the US Market for Chlamydia Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Thermo Electron, Wampole / Inverness Medical Innovations, and Quidel (includes corresponding Graph/Chart)
  • Table 34: Leading Players in the US Market for Syphilis Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Wampole/Inverness Medical Innovations, and Others (includes corresponding Graph/Chart)
  • Leading Players in HIV Rapid Testing Market
  • Gastrointestinal Rapid Tests
  • Market Share Trends of Leading Players
  • Table 35: Leading Players in the US Market for C. Difficile Rapid Tests (2004 & 2005) -Percentage Breakdown of Value Sales by Company for Wampole/Inverness Medical Innovations, Meridian Biosciences, BioSite, Becton Dickinson, Thermo Electron, and Others (includes corresponding Graph/Chart)
  • Table 36: Leading Players in the US Market for Cryptosporidium Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes correspondingGraph/Chart)
  • Table 37: Leading Players in the US Market for Rotavirus Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, FisherScientific, and Others (includes corresponding Graph/Chart)
  • Table 38: Leading Players in the US Market for Giardia Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes corresponding Graph/Chart)
  • Respiratory Rapid Tests
  • Competition:
  • Table 39: Leading Players in the US Market for Influenza Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Quidel, Becton Dickinson, Thermo Electron, Binax and Others (includes corresponding Graph/Chart)
  • Table 40: Leading Players in the US Market for RSV Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Binax, Thermo Electron and Others (includes corresponding Graph/Chart)
  • Table 41: Leading Players in the US Market for Tuberculosis Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Gen-Probe, and Becton Dickinson
  • Table 42: Leading Players in the US Market for M. Pneumoniae Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, and Remel, Inc.
  • Table 43: Leading Players in the US Market for Mononucleosis Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Wampole, Remel, Quidel, Thermo Electronand Others (includes corresponding Graph/Chart)
  • Streptococcus Infection Rapid Tests
  • Table 44: Leading Players in the US Market for Streptococcus A Rapid Tests (2004 & 2005) - Percentage Breakdown of Value Sales by Company for Quidel, Thermo Electron, Becton Dickinson, Genzyme and Others (includes corresponding Graph/Chart)
  • Average Prices
  • Table 45: Average Costs for Rapid Tests in the US (includes corresponding Graph/Chart)
  • A Peek into the Testing Practices of the US Food Industry
  • Table 46: Microbiology Tests in the US Food Industry by Sector: 2001 (includes corresponding Graph/Chart)
  • Product Innovations/Introductions
  • Strategic Corporate Developments
  • Focus on Key Players
  • Abbott Laboratories
  • Abbott Diagnostics
  • Arlington Scientific, Inc.
  • Becton Dickinson And Company
  • bioMerieux, Inc.
  • Bio-Rad Laboratories
  • Gen-Probe Incorporated
  • Genzyme Diagnostics
  • Inverness Medical Innovations, Inc
  • Meridian Biosciences, Inc.
  • Orasure Technologies, Inc.
  • Quidel Corporation
  • Remel Inc.
  • Siemens Healthcare Diagnostics
• B. Market Analytics
  • Table 47: US Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 48: US Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 49: US 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, C/Chlamydia Rapid Tests, and Other Automated & Rapid MicrobiologicalTests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
  • Table 50: US Recent Past, Current & Future Market Analysis for Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 51: US Long-term Projections for Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications IndependentlyAnalyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 52: US 10-Year Perspective for Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications for2003, 2008 & 2012 (includes corresponding Graph/Chart)

2. Europe

• A. Market Analysis
  • A Current & Future Analysis
  • European Market Primer
  • What Drives the Requirement Patterns of End-Users?
  • Competitive Profile ...
  • Table 53: Leading Players in European Market for Automated & Rapid Microbiological Tests (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Becton Dickinson, Organon Teknika, Merlin, Abbott, Dade, Unipath, and Others(includes corresponding Graph/Chart)
  • Trends & Issues
  • Proliferation of Automated, and Rapid Tests in Europe...
  • European Automated Market
  • Probe Tests: "A Crack in the Future of Rapid Tests"
  • Trends Across Product Segments
  • GC/Chlamydia Rapid Tests
  • Streptococcal Infection (Strep A) Rapid Tests
  • Automated Tuberculosis Systems Market
  • Historic Competitive Profile
  • Table 54: Leading Players in European Market for Chlamydia Rapid Tests (2000) - Percentage Breakdown of Value Sales by Company for Abbott, Oxoid, Unipath, Quidel, and Others (includes corresponding Graph/Chart)
  • Table 55: Leading Players in European Market for Streptococcal Infection (Strep A) Rapid Tests (2000) - Percentage Breakdown of Value Sales by Company for Abbott, Unipath, Quidel, Orion Diagnostics, Oxoid, and Becton Dickinson (includes corresponding Graph/Chart)
  • Table 56: Leading Players in European Market for Automated Blood Culture Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Organon Teknika, and bioMerieux (includes corresponding Graph/Chart)
  • Product Innovations/Introductions
• B. Market Analytics
  • Table 57: European Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Revenuesin US$ Million for Years 2000 through 2010(includes corresponding Graph/Chart)
  • Table 58: European Long-term Projections for Automated &Rapid Microbiological Tests by Geographic Region - France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed withAnnual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 59: European Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 60: European Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests,and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 61: European 10-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Revenues for France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
  • Table 62: European 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal InfectionRapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2a. France

• A. Market Analysis
  • A Current & Future Analysis
  • Leading Players in Select Segments -Historic Data
  • Table 63: Leading Players in French Market for Automated & Rapid Microbiological Tests (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Becton Dickinson, Merlin, Organon Teknika, Dade, Pasteur Sanofi Diagnostic, Oxoid and Abbott (includes corresponding Graph/Chart)
  • Chlamydia Rapid Tests
  • Table 64: Leading Players in French Market for Chlamydia Rapid Tests (2000) - Percentage Breakdown of Value Salesby Company for Oxoid and Others
  • Automated Tuberculosis Systems
  • Table 65: Leading Players in French Market for Automated Tuberculosis Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson and Others
  • Automated Blood Culture Systems
  • Table 66: Leading Players in French Market for Automated Blood Culture Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Organon Teknika, bioMerieux, and Pasteur Sanofi Diagnostic (includes corresponding Graph/Chart)
  • Automated Identification and Susceptibility Systems
  • Table 67: Leading Players in French Market for Automated Identification and Susceptibility Systems (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Merlin, Dade, and Becton Dickinson (includes corresponding Graph/Chart)
  • bioMerieux: A Key Player
  • Product Innovations/Introductions
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 68: French Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 69: French Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 70: French 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2b. Germany

• A. Market Analysis
  • A Current & Future Analysis
  • Competitive Structure...
  • Leading Players in Select Segments - Historic Data
  • Table 71: Leading Players in German Market for Automated & Rapid Microbiological Tests (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Organon Teknika, Becton Dickinson,Merlin, Abbott, Unipath, and Others (includes corresponding Graph/Chart)
  • Streptococcal Infection Rapid Tests
  • Table 72: Leading Players in German Market for Streptococcal Infection Rapid Tests (2000) Percentage Breakdown of Value Sales by Company for Abbott, Unipath and Quidel (includes corresponding Graph/Chart)
  • Automated Tuberculosis System
  • Table 73: Leading Players in German Market for Automated Tuberculosis Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinsonand Others
  • Automated Blood Culture Systems
  • Table 74: Leading Players in German Market for Automated Blood Culture Systems (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Becton Dickinson, and Organon Teknika (includes corresponding Graph/Chart)
  • Chlamydia Rapid Tests
  • Table 75: Leading Players in German Market for Chlamydia Rapid Tests (2000) - Percentage Breakdown of Value Sales by Company for Abbott, Unipath, Quidel, Orgenics and International Microbio (includes corresponding Graph/Chart)
  • Automated Identification and Susceptibility Systems
  • Table 76: Leading Players in German Market for Automated Identification and Susceptibility Systems (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Merlin and Dade (includes corresponding Graph/Chart)
  • Merlin Diagnostica GmbH - A Key Player
• B. Market Analytics
  • Table 77: German Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includescorresponding Graph/Chart)
  • Table 78: German Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 79: German 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection RapidTests, GC/Chlamydia Rapid Tests, and OtherAutomated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2c. The United Kingdom

• A. Market Analysis
  • A Current & Future Analysis...
  • Increasing Incidence of MRSA Spur Growth in Rapid Diagnostics
  • Leading Players in Select Segments - Historic Data
  • Table 80: Leading Players in the UK Market for Automated & Rapid Microbiological Tests (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Becton Dickinson, Organon Teknika, Unipath, Abbott, and Others (includes corresponding Graph/Chart)
  • Chlamydia Rapid Tests
  • Table 81: Leading Players in the UK Market for Chlamydia Rapid Tests (2000)) - Percentage Breakdown of Value Sales by Company for Abbott, Unipath, Quidel, Orgenics and International Microbio (includes corresponding Graph/Chart)
  • Automated Tuberculosis System
  • Table 82: Leading Players in the UK Market for Automated Tuberculosis Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, and Others
  • Automated Identification and Susceptibility Systems
  • Table 83: Leading Players in the UK Marketfor Automated Identification and Susceptibility Systems (2000 & 2004) - Percentage Breakdown of Value Sales by Company for bioMerieux, and Becton Dickinson
  • Streptococcal Infection Rapid Tests
  • Table 84: Leading Players in the UK Market for Streptococcal Infection Rapid Tests (2000) - Percentage Breakdown of Value Sales by Company for Unipath and Abbott
  • Automated Blood Culture Systems
  • Table 85: Leading Players in the UK Market for Automated Blood Culture Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Organon Teknika, and bioMerieux (includes corresponding Graph/Chart)
  • Product Innovation/Introduction
  • Strategic Corporate Developments
  • Focus on Select Players
  • Celsis International Plc
  • Oxoid Limited
• B. Market Analytics
  • Table 86: UK Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 87: UK Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 88: UK 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests,GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-ClinicalApplications for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2d. Italy

• A. Market Analysis
  • A Current & Future Analysis...
  • Leading Players in Select Segments-- Historic Data
  • Table 89: Leading Players in Italian Market for Automated & Rapid Microbiological Tests (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, bioMerieux, OrganonTeknika, Dade, Abbott, Unipath, and Quidel (includes corresponding Graph/Chart)
  • Streptococcal Infection Rapid Tests
  • Table 90: Leading Players in Italian Market for Streptococcal Infection Rapid Tests (2000) - Percentage Breakdown of Value Sales by Company for Abbott, Unipath, Becton Dickinson and Quidel (includes corresponding Graph/Chart)
  • Automated Tuberculosis System
  • Table 91: Leading Players in Italian Market for Automated Tuberculosis Systems (2000) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, and Others
  • Chlamydia Rapid Tests
  • Table 92: Leading Players in Italian Market for Chlamydia Rapid Tests (2000) - Percentage Breakdownof Value Sales by Company for Unipath, Abbott, and Biolife (includes corresponding Graph/Chart)
• B. Market Analytics
  • Table 93: Italian Recent Past, Current & Future Market Analysis for Automated & Rapid MicrobiologicalTests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, AutomatedTuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-ClinicalApplications Independently Analyzed with AnnualRevenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 94: Italian Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 95: Italian 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems,Automated Tuberculosis Systems, StreptococcalInfection Rapid Tests, GC/Chlamydia Rapid Tests,and Other Automated & Rapid Microbiological Tests)and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2e. Spain

• A. Market Analysis
  • A Current & Future Analysis...
  • Market Share Trends of Leading Players- Historic Data
  • Table 96: Leading Players in Spanish Market for Automated Tuberculosis Systems (2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, Organon Teknika, and Becton Dickinson (includes corresponding Graph/Chart)
• B. Market Analytics
  • Table 97: Spanish Recent Past, Current & FutureMarket Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, AutomatedTuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-ClinicalApplications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 98: Spanish Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 99: Spanish 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal InfectionRapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2f. Russia

• Market Analysis
• A Current & Future Analysis...
• Table 100: Russian Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, C/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 101: Russian Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 102: Russian 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2g. Rest of Europe

• A. Market Analysis
  • A Current & Future Analysis...
  • Leading Players in Select Segments- Historic Data
  • Streptococcal Infection Rapid Tests
  • Table 103: Leading Players in Streptococcal Infection Rapid Tests Market in Rest of Europe (2000) - Percentage Breakdown of Value Sales by Company for Abbott, and Oxoid
  • Automated Identification and Susceptibility Systems
  • Table 104: Leading Players in Automated Identificationand Susceptibility Systems Market in Rest of Europe(2000) - Percentage Breakdown of Value Sales by Company for bioMerieux, and Becton Dickinson
  • Product Innovations/Introductions
  • Strategic Corporate Developments
  • Focus on Select Players
  • Coris BioConcept (Belgium)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Orion Diagnostica Oy (Finland)
• B. Market Analytics
  • Table 105: Rest of Europe Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 106: Rest of Europe Long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 107: Rest of Europe 10-Year Perspective for Automated & Rapid Microbiological Tests by Product Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Rest of World

• A. Market Analysis
  • A Current & Future Analysis...
  • Latin American Market
  • Asia-Pacific - The Next Epicenter for the AIDS Epidemic...
  • Product Innovations/Introductions
  • Strategic Corporate Developments
  • Focus on Select Players
  • Cellabs Pty Ltd (Australia)
  • MedMira Inc. (Canada)
• B. Market Analytics
  • Table 108: Rest of World Recent Past, Current & Future Market Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2000 through2010 (includes corresponding Graph/Chart)
  • Table 109: Rest of World long-term Projections for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 110: Rest of World 10-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2008 & 2012 (includes corresponding Graph/Chart)